DALLAS, Nov. 18, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Cerus Corp. (Nasdaq:CERS - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

The investment report on Cerus Corp. (Nasdaq:CERS - News) should be of particular interest to other biotechnology and drug companies: Gen-Probe Inc. (Nasdaq:GPRO - News), Haemonetics Corp. (NYSE:HAE - News) and Pall Corp. (NYSE:PLL - News).

The full report is available at: http://www.beaconequity.com/i/CERS

Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity

Cerus Corp. (CERS) is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company markets the INTERCEPT system for both platelets and plasma in Europe and the Middle East. CERS is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is in clinical development.

Message Board Search for CERS: http://www.boardcentral.com/boards/CERS

In the report, the analyst notes:

Total revenue for the third quarter of 2009 was $4.8 million, up from $3.9 million in revenue recognized during the third quarter of 2008. Total revenue for the first nine months of 2009 was $12.5 million, down from $12.9 million recognized during the first nine months of 2008, when $1.5 million of previously deferred product revenue was recognized.

"CERS announced today that the FDA's Blood Products Advisory Committee (BPAC) rendered a positive opinion on the proposed hemostatic efficacy and safety endpoints for a potential U.S. phase III clinical trial of the INTERCEPT Blood System for platelets. The Committee disagreed with the safety margins for the trial proposed by CERS, and recommended that the trial design include more stringent safety margins for comparing INTERCEPT-treated platelets and conventional platelets. In addition, the Committee rendered a positive opinion on a proposed pathway forward in which successful completion of the proposed phase III trial would be followed by a post-marketing randomized control study and concurrent staged roll-out of the product."

To read the entire report visit: http://www.beaconequity.com/i/CERS

See what investors are saying about these stocks at: http://www.stockhideout.com/

BeaconEquity.com is one of the industry's largest small-cap report providers striving to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information, please visit http://www.BeaconEquity.com

Beacon Equity Disclosure

DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.